Feasibility Study of Uterus Transplantation Procedure From a Live Donor Obtaining the Graft by Laparoscopy

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Absolut uterine factor, meaning the absence of uterus, represents a cause for sterility without the possibility of a present treatment. The uterine factor affects millions of women and may be due to congenital problems, such as the Muller anomalies (Mayer Rockitansky Syndrome) or acquired by previous hysterectomy or intrauterine adhesions (Asherman's Syndrome). The uterine transplant would represent the only possibility for patients with an absolute uterine factor to achieve both genetic and gestational maternity.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Patient with sterility for absolute uterine factor (malformation or previous surgery for benign processes).

• Age \<40 years.

• Absence of pathology that contraindicates a complex surgical process, immunosuppression or gestation.

• Positive results to the IVF cycle prior to the surgery, obtaining quality embryos.

• Acceptance to participate in the study signing the informed consent.

• Age \<65 years.

• First- or second-degree relatives.

• Completed reproductive desire.

• History of previous pregnancies and births.

• Absence of associated pathology that contraindicates prolonged and complex laparoscopic surgery (pneumopathies, heart disease, morbid obesity, …).

• Acceptance to participate in the study signing the informed consent

Locations
Other Locations
Spain
Hospital Clinic
RECRUITING
Barcelona
Contact Information
Primary
Mariona Rius, MD
marius@clinic.cat
932275400
Time Frame
Start Date: 2020-05-23
Estimated Completion Date: 2025-12
Participants
Target number of participants: 10
Treatments
Experimental: Recipient
Patient with absolut uterine factor will undergo uterus transplantation.
Sponsors
Leads: Hospital Clinic of Barcelona

This content was sourced from clinicaltrials.gov